AstraZeneca pledges more Evusheld doses to US, bringing its antibody supply deal to $855Mnews2022-02-14T14:47:53+00:00February 14th, 2022|Fierce Pharma|
Moderna eyes UK for next leg of mRNA vaccine manufacturing journey: reportnews2022-02-14T13:59:17+00:00February 14th, 2022|Fierce Pharma|
ASCO GU: J&J plays up precision therapy approach for Zejula’s prostate cancer bid after mixed resultsnews2022-02-14T10:05:42+00:00February 14th, 2022|Fierce Pharma|
Xanadu spins out of Yale with nasal COVID-19 vaccine tech, teeing up push to curb viral transmissionnews2022-02-14T09:38:45+00:00February 14th, 2022|Fierce Pharma|
Opiant’s nasal opioid overdose drug clears PK test, edges closer to FDA filingnews2022-02-14T09:35:01+00:00February 14th, 2022|Fierce Pharma|
FDA signs off on Lilly’s new antibody drug, bebtelovimab, which is effective against the omicron variantnews2022-02-11T22:32:00+00:00February 11th, 2022|Fierce Pharma|
Pfizer’s and Lilly’s JAK inhibitor safety concerns prompt Europe to scrutinize drug classnews2022-02-11T20:33:33+00:00February 11th, 2022|Fierce Pharma|
Pfizer and Lilly’s JAK inhibitor safety concerns prompt Europe to scrutinize drug classnews2022-02-11T20:33:33+00:00February 11th, 2022|Fierce Pharma|
Pfizer stalls COVID-19 vaccine app as it awaits data on third dose in young kidsnews2022-02-11T19:41:07+00:00February 11th, 2022|Fierce Pharma|
FDA sets an example through Eli Lilly, Innovent’s PD-1, rocking the boat for future contenders: analystnews2022-02-11T16:28:44+00:00February 11th, 2022|Fierce Pharma|
